Friday, 8 August 2025
  
Login

Australia's most trusted
source of pharma news

Friday, 08 August 2025
News

Another funding path for Wegovy?

Posted 7 August 2025 AM

New indications for semaglutide are being touted even as competing GLP-1RAs enter the weight loss arena and generics of the drug circle, with the latest efforts looking at cerebrovascular disease management.

Recent clinical findings suggest semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy, is a promising candidate for neurological conditions, with key opinion leaders saying the potential in brain diseases seems to be based on its anti-inflammatory action.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (3)

Sales & Customer Relations (15)

Clinical & Medical, R&D (6)

Regulatory, Pharmacovigilance & QA (6)

Devices (1)

Other (13)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.